Why Canopy Growth Stock May Be in for Some Downside Pressure From Here

Here’s why more downside may be on the horizon for Canopy Growth Corp. (TSX:WEED)(NYSE:CGC).

Despite an incredible start to the year, Canopy Growth (TSX: WEED)(NYSE:CGC) has waned in recent months. Shares of this Canadian cannabis juggernaut have fallen nearly 60% from their peak earlier this year. Indeed, the entire cannabis sector, particularly in Canada, has felt this pain.

Unfortunately, more pain may be on the horizon for these stocks. And Canopy’s current position as a dominant Canadian cannabis player puts this stock more in the limelight than its peers. Here’s why I’m more bearish on this stock than I have been in some time.

Fourth-quarter earnings did not meet expectations

As with any publicly traded company, earnings matter. While one could argue that earnings have taken a back seat for cannabis companies in recent years, investors are largely assessing these equities on the basis of how profitably they’re growing in addition to how fast they’re growing.

For investors in Canopy, the numbers simply don’t look great.

The company reported lower-than-anticipated earnings this most recent quarter. Both revenue and EBITDA failed to meet analyst expectations. In fact, the company’s EBITDA loss of $94 million was the highlight many investors seem to have jumped on. Despite a series of cost-cutting measures, Canopy hasn’t been able to stem the bleeding thus far. There’s a lot of work to be done to get this company to operate with a positive operating margin. Accordingly, many fundamental investors remain on the sidelines with this stock.

Now, Canopy has announced a cost-cutting plan of reducing $150 million of expenses by fiscal 2022. That’s good. And the company’s recent acquisitions of Supreme and Ace Valley could provide some EBITDA growth (positive). That would be good as well.

However, analysts remain fuzzy on how to quantify or project positive EBITDA for Canopy from here. Some suggest the company needs to drastically reduce costs or cut out its M&A activity. After all, Canopy is burning through cash at a rate of approximately $400 million in 2022 and $125 million in 2023. This cash will need to come from somewhere, leading many to believe more debt and/or another equity issuance could be on the horizon for investors.

Such moves may be difficult for investors to stomach over the short term. Accordingly, it’s hard to be bullish on this stock over the next 12 months, in my view.

Bottom line

Besides these rather disappointing fundamentals, the U.S. legalization catalyst many investors were banking on appears to be less of a sure thing than it once was. There happens to be no shortage of negative catalysts for cannabis players like Canopy right now.

Accordingly, this is a stock many investors may do well to stay on the sidelines with. There’s simply too much near-term uncertainty with this stock to warrant an investment today, in my view.

Fool contributor Chris MacDonald has no position in any stocks mentioned in this article.

More on Cannabis Stocks

Medicinal research is conducted on cannabis.
Cannabis Stocks

Top Canadian Stocks to Buy Right Now With $1,000

Cannara, Source Energy and CareRx just updated investors. See what $1,000 can buy in these Canadian stocks, plus the risks…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Stocks for Beginners

This Cannabis Stock Jumped 12% in a Day: The Math Says Be Careful

Tilray's record revenue came with declining cannabis sales and negative free cash flow, making the investment much more speculative than…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Curaleaf’s Takeover Bid for Aurora Cannabis: What Investors Need to Know

Curaleaf's takeover bid for Aurora Cannabis offers a premium but brings stock, debt, and deal risks. Here’s what ACB investors…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Curaleaf Just Announced a Hostile Takeover Bid for Aurora Cannabis. Here’s What This Means for Investors.

It's appealing directly to the Canadian company's shareholders with a cash-and-stock offer.

Read more »

runner checks her biodata on smartwatch
Cannabis Stocks

Average TFSA and RRSP Balances at Age 45: Are You on Par?

Most 45-year-olds have less than $100,000 combined in their TFSA and RRSP. Here's how TerrAscend could help you close the…

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Risky Stocks That Could Send Your $100,000 Investment to $0

Cannabis stocks look risky because price wars, dilution, and regulation can turn one weak quarter into a long drawdown.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

My Biggest Investing Regret in 2025 Was Buying This Stock

Canopy Growth is a cautionary reminder to buy businesses, not headlines, especially in hype-driven sectors like cannabis.

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Popular Stocks That Could Wipe Out a $100,000 Nest Egg

Aurora Cannabis (TSX:ACB) is one stock that could wipe out your nest egg.

Read more »